ÂÜÀòÂÒÂ×

Michael Cohen-Wolkowiez has a diverse work experience spanning over several prestigious organizations and roles. Michael is currently serving as the Chief Medical Advisor at Lightship® since May 2022. Prior to that, they held various positions at Duke Clinical Research Institute, including Head of Pediatrics, Co-Director of Transformation, Director of the Pharmacometrics Center, and Director of Duke Early Phase Clinical Research. In these roles, they demonstrated strong leadership skills, overseeing multiple projects, managing cross-functional teams, and fostering relationships with pharmaceutical companies.

Before joining Duke, Michael Cohen-Wolkowiez worked at Duke University, where they held the positions of Distinguished Professor, Professor of Pediatrics, Associate Professor of Pediatrics, and Assistant Professor of Pediatrics. Their contributions to the field of pediatrics are evident through their various academic positions at Duke University.

Furthermore, Michael Cohen-Wolkowiez has had experience working for the FDA as a Scientific Advisor. During their time there, they closely collaborated with the Office of Pediatric Therapeutics and the Office of Clinical Pharmacology, contributing their expertise to pediatric drug approvals and conducting clinical pharmacology research.

Overall, Michael Cohen-Wolkowiez's work experience reflects their expertise in the field of pediatrics, their leadership and managerial capabilities, and their commitment to advancing medical research and drug development.

Michael Cohen-Wolkowiez has a diverse education history. Michael began their educational journey in 1994 at the Universidad Central de Venezuela, where they pursued a degree in Medicine. From 2002 to 2005, they enrolled in the Pediatrics Residency Program at Miami Children's Hospital, where they earned a Residency degree. Following this, from 2005 to 2006, they continued their training in the same program and obtained the position of Chief Resident. Michael then pursued further specialization at Duke University from 2006 to 2009, where they completed the Pediatric Infectious Diseases Residency Program. Lastly, they attended the University of North Carolina at Chapel Hill from 2007 to 2012, where they obtained a Doctor of Philosophy (Ph.D.) degree in Pharmaceutical Sciences.